A Study of MUSE Device for Midlife Women
MUSE Device to Improve Sleep Quality in Midlife Women
1 other identifier
interventional
31
1 country
1
Brief Summary
The purpose of this study is to see if it is feasible for midlife women to wear a brain activity sensing headband (Muse-S) for management of sleep disturbances such as insomnia and sleep disruption
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Aug 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 25, 2023
CompletedStudy Start
First participant enrolled
August 1, 2023
CompletedFirst Posted
Study publicly available on registry
August 2, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 12, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 12, 2025
CompletedResults Posted
Study results publicly available
January 26, 2026
CompletedJanuary 26, 2026
January 1, 2026
1.5 years
July 25, 2023
January 8, 2026
January 8, 2026
Conditions
Outcome Measures
Primary Outcomes (2)
Change in Quality of Sleep
Measured using the self-reported Pittsburgh Sleep Quality Index (PSQI) to assess the severity of sleep disturbances. Possible scores range from 0 to 21 with higher scores indicating a worse outcome/more severe symptoms of sleep disturbance.
Baseline, 3 months, 6 months
Sleep Impact
Measured using the self-reported ASCQ-Me Sleep Impact Short Form. The 5-item questionnaire used to assess functioning and wellbeing in accordance with sleep. The questions in this assessment tool ask how often they felt sleep impacted specific activities during the the past 7 days. Possible answers include: 5 - never; 4 - rarely; 3 - sometimes; 2 - often, and 1 - always. Possible scores range from 5 to 25, with higher scores indicating a better outcome.
Baseline, 3 months, 6 months
Secondary Outcomes (5)
Perceived Stress Levels
Baseline, 3 months, 6 months
Change in Perceived Anxiety
Baseline, 3 months, 6 months
Sexual Function
Baseline, 3 months, 6 months
Sexual Distress
Baseline, 3 months, 6 months
Change in Quality of Life
Baseline, 3 months, 6 months
Study Arms (1)
Muse-S headband system for management of sleep disturbances
EXPERIMENTALStudy participants will receive a new Muse-S headband system at study entry and will be asked to utilize it daily for a minimum of 10 minutes day for a period of 6 months (24 weeks). Three of the seven sessions per week will specifically be asked to be mind meditation.
Interventions
Clinical grade, headband-style wireless EEG (electroencephalogram is a test used to evaluate the electrical activity in the brain) system and designed to interact with a mobile device (a smartphone or tablet). The device is a soft, stretchy band that fits around the forehead to the back of the head.
Eligibility Criteria
You may qualify if:
- Women in the menopause transition or in menopause, based on clinical assessment
- PSQI score \> 5, with overall sleep quality rating of "fairly bad" or "very bad".
- Motivation VAS score equal to or greater than 5 with overall motivation rating of on a scale of 0-10 with 0 being not motivated at all and 10 being extremely motivated.
- Access to an iPad, iPhone, or android device.
- Have ability to provide informed consent.
You may not qualify if:
- Suspected or untreated obstructive sleep apnea.
- Moderate to severe vasomotor symptoms warranting prescription medication use. The FDA categories for hot flash severity are classified as mild (sensation of heat without sweating), moderate (sensation of heat with sweating, able to continue activity), or severe (sensation of heat with sweating cause cessation of activity).
- Use of hormone therapy or hypnotic agents.
- Use of supplements known to affect sleep.
- A known, active, untreated clinically significant psychiatric condition.
- Use of an investigational drug within 30 days of study enrollment or presence of a known history of any condition or factor judged by the investigator to preclude participation in the study or which might hinder adherence.
- Currently (within the past 3 weeks) been practicing mindfulness training on a weekly/regular basis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Study Sites (1)
Mayo Clinic Minnesota
Rochester, Minnesota, 55905, United States
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Amber Klindworth, P.A.-C.
- Organization
- Mayo Clinic
Study Officials
- PRINCIPAL INVESTIGATOR
Amber Klindworth, PA-C
Mayo Clinic
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
July 25, 2023
First Posted
August 2, 2023
Study Start
August 1, 2023
Primary Completion
January 12, 2025
Study Completion
January 12, 2025
Last Updated
January 26, 2026
Results First Posted
January 26, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share